Oculogenex
PrivateLast Round
Grant
May 1, 2022
Total Funding Raised
$1.28M
Company Overview
Oculogenex operates in Healthcare & Life Sciences and is based in La Habra, California. Its latest recorded funding round was a Grant round in May 2022.
Oculogenex is a biotechnology company developing a regenerative gene therapy to treat retinal disorders such as dry age-related macular degeneration.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Space Technology, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Oculogenex Comparables
Compare Oculogenex with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Perceive Biotherapeutics, Inc. | 84% | |
| Complement Therapeutics GmbH | 82% | |
| Beacon Therapeutics | 81% |
For institutional investors. Book with your work email.
Oculogenex Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | May 1, 2022 | ||||
| Grant | Oct 28, 2021 | ||||
| Grant | May 1, 2021 | ||||
| Grant | Feb 6, 2021 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Oculogenex Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| MassChallenge Israel | Grant |
| The Winning Pitch Challenge | Grant |
| National Science Foundation | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- May 1, 2022
Received $1M grant from the National Science Foundation.
- Nov 2, 2021
Received grant funding from Boeing and MassChallenge.
For institutional investors. Book with your work email.
Oculogenex Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Oculogenex's valuation, stock price, and market status.
Is Oculogenex a public or private company?
Oculogenex is a private company.
What is the current stock price of Oculogenex?
Oculogenex is a private company, so its shares have no public market price. Caplight tracks Oculogenex's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Oculogenex worth (valuation)?
Valuation information for Oculogenex is not publicly available.
Can I buy Oculogenex stock?
Oculogenex shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Oculogenex's last funding round?
Oculogenex's most recent funding round was Grant on May 1, 2022.
Who are the main investors in Oculogenex?
Key investors in Oculogenex include The Winning Pitch Challenge, National Science Foundation.
Will Oculogenex IPO soon?
No public IPO plans have been announced for Oculogenex.
How can I track Oculogenex secondary market activity?
Caplight tracks bids, offers, and trades in Oculogenex's shares on secondary markets.